Filing Details

Accession Number:
0000919574-18-008210
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-12-28 17:30:23
Reporting Period:
2018-12-26
Accepted Time:
2018-12-28 17:30:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1183765 Molecular Templates Inc. MTEM Pharmaceutical Preparations (2834) 943409596
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1325713 Bruce Kovner C/O Caxton Corporation
731 Alexander Road, Bldg. 2
Princeton NJ 08540
Yes No No No
1388551 Caxton Corp 731 Alexander Road
Building 2
Princeton NJ 08540
Yes No No No
1576081 Cdk Associates, L.l.c. C/O Caxton Corporation
731 Alexander Road, Bldg. 2
Princeton NJ 08540
Yes No No No
1576113 D Scott Morenstein C/O Caxton Alternative Management Lp
1330 Sixth Avenue, 20Th Floor
New York NY 10019
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-12-26 25,000 $3.45 1,584,241 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Footnotes
  1. These shares are held by CDK Associates, L.L.C. and may be deemed to be beneficially owned by (i) Scott Morenstein, a Managing Director of Caxton Alternative Management LP, the investment manager of CDK Associates, L.L.C., (ii) Caxton Corporation, the manager of CDK Associates, LLC and (iii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation. Scott Morenstein serves as a director of the Issuer. Caxton Corporation, Bruce Kovner and CDK Associates, L.L.C. may be considered directors by deputization due to their affiliation with Scott Morenstein. Each Reporting Person disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.